Neuphoria Therapeutics Stock Market Value
| NEUP Stock | 3.72 0.07 1.85% |
| Symbol | Neuphoria |
Neuphoria Therapeutics Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neuphoria Therapeutics. If investors know Neuphoria will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neuphoria Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Neuphoria Therapeutics is measured differently than its book value, which is the value of Neuphoria that is recorded on the company's balance sheet. Investors also form their own opinion of Neuphoria Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Neuphoria Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neuphoria Therapeutics' market value can be influenced by many factors that don't directly affect Neuphoria Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neuphoria Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Neuphoria Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neuphoria Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Neuphoria Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Neuphoria Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Neuphoria Therapeutics.
| 11/27/2025 |
| 12/27/2025 |
If you would invest 0.00 in Neuphoria Therapeutics on November 27, 2025 and sell it all today you would earn a total of 0.00 from holding Neuphoria Therapeutics or generate 0.0% return on investment in Neuphoria Therapeutics over 30 days. Neuphoria Therapeutics is related to or competes with Pheton Holdings, Inspira Technologies, Biomerica, Aprea Therapeutics, Innovative Eyewear, Biocardia, and Alzamend Neuro. Neuphoria Therapeutics is entity of United States More
Neuphoria Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Neuphoria Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Neuphoria Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.04) | |||
| Maximum Drawdown | 101.43 | |||
| Value At Risk | (11.34) | |||
| Potential Upside | 17.47 |
Neuphoria Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Neuphoria Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Neuphoria Therapeutics' standard deviation. In reality, there are many statistical measures that can use Neuphoria Therapeutics historical prices to predict the future Neuphoria Therapeutics' volatility.| Risk Adjusted Performance | (0.02) | |||
| Jensen Alpha | (0.61) | |||
| Total Risk Alpha | (1.79) | |||
| Treynor Ratio | (0.24) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Neuphoria Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Neuphoria Therapeutics Backtested Returns
Neuphoria Therapeutics has Sharpe Ratio of -0.0476, which conveys that the firm had a -0.0476 % return per unit of risk over the last 3 months. Neuphoria Therapeutics exposes twenty-two different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please verify Neuphoria Therapeutics' Standard Deviation of 13.19, risk adjusted performance of (0.02), and Mean Deviation of 6.55 to check out the risk estimate we provide. The company secures a Beta (Market Risk) of 1.97, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Neuphoria Therapeutics will likely underperform. At this point, Neuphoria Therapeutics has a negative expected return of -0.64%. Please make sure to verify Neuphoria Therapeutics' maximum drawdown, daily balance of power, as well as the relationship between the Daily Balance Of Power and period momentum indicator , to decide if Neuphoria Therapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.53 |
Modest predictability
Neuphoria Therapeutics has modest predictability. Overlapping area represents the amount of predictability between Neuphoria Therapeutics time series from 27th of November 2025 to 12th of December 2025 and 12th of December 2025 to 27th of December 2025. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Neuphoria Therapeutics price movement. The serial correlation of 0.53 indicates that about 53.0% of current Neuphoria Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.53 | |
| Spearman Rank Test | 0.36 | |
| Residual Average | 0.0 | |
| Price Variance | 0.01 |
Neuphoria Therapeutics lagged returns against current returns
Autocorrelation, which is Neuphoria Therapeutics stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Neuphoria Therapeutics' stock expected returns. We can calculate the autocorrelation of Neuphoria Therapeutics returns to help us make a trade decision. For example, suppose you find that Neuphoria Therapeutics has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Neuphoria Therapeutics regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Neuphoria Therapeutics stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Neuphoria Therapeutics stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Neuphoria Therapeutics stock over time.
Current vs Lagged Prices |
| Timeline |
Neuphoria Therapeutics Lagged Returns
When evaluating Neuphoria Therapeutics' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Neuphoria Therapeutics stock have on its future price. Neuphoria Therapeutics autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Neuphoria Therapeutics autocorrelation shows the relationship between Neuphoria Therapeutics stock current value and its past values and can show if there is a momentum factor associated with investing in Neuphoria Therapeutics.
Regressed Prices |
| Timeline |
Pair Trading with Neuphoria Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Neuphoria Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Neuphoria Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Neuphoria Stock
Moving against Neuphoria Stock
| 0.7 | VCEL | Vericel Corp Ord | PairCorr |
| 0.64 | VCYT | Veracyte | PairCorr |
| 0.56 | VKTX | Viking Therapeutics | PairCorr |
| 0.53 | DSGN | Design Therapeutics | PairCorr |
| 0.52 | DVAX | Dynavax Technologies Trending | PairCorr |
The ability to find closely correlated positions to Neuphoria Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Neuphoria Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Neuphoria Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Neuphoria Therapeutics to buy it.
The correlation of Neuphoria Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Neuphoria Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Neuphoria Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Neuphoria Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Neuphoria Stock Analysis
When running Neuphoria Therapeutics' price analysis, check to measure Neuphoria Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neuphoria Therapeutics is operating at the current time. Most of Neuphoria Therapeutics' value examination focuses on studying past and present price action to predict the probability of Neuphoria Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neuphoria Therapeutics' price. Additionally, you may evaluate how the addition of Neuphoria Therapeutics to your portfolios can decrease your overall portfolio volatility.